LD
Therapeutic Areas
Immatics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| IMA203 (ACTengine®) | Recurrent/refractory solid tumors (melanoma, ovarian, HNSCC, uveal melanoma) | Phase 1b |
| IMA203CD8 (ACTengine®) | Recurrent/refractory solid tumors | Phase 1 |
| IMA204 (ACTengine®) | Synovial sarcoma, Myxoid/Round Cell Liposarcoma (MRCLS) | Phase 1 |
| IMA401 (TCR Bispecific) | Advanced solid tumors (NSCLC, SCCHN, ovarian, bladder) | Phase 1/2 |
| IMA402 (TCR Bispecific) | Advanced solid tumors | Phase 1 |
| IMA403 (TCR Bispecific) | Advanced solid tumors | Pre-clinical |
| IMA30X Series (ACTengine®) | Various solid tumors | Pre-clinical |
Leadership Team at Immatics
HS
Harpreet Singh
Chief Executive Officer & Chief Scientific Officer
CB
Cedrik Britten
Chief Medical Officer
PP
Paul Parren
Executive Vice President & Chief Scientific Officer of TCR Bispecifics
CR
Carsten Reinhardt
Chief Development Officer
AR
Alessandro Riva
Chairman of the Board of Directors
WF
Wolfgang Fischer
Chief Operating Officer
MK
Matthew K. Robinson
President & Chief Operating Officer, Immatics US, Inc.
SW
Sascha W. Reinhardt
Chief Financial Officer
VB
Vered Bisker-Leib
Executive Vice President & Chief Operating Officer
AM
Angela M. Steinway
General Counsel & Chief Compliance Officer